NIAID signs multimillion-dollar deal with ATCC

By The Science Advisory Board staff writers

November 23, 2021 -- The U.S. National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health, awarded a seven-year contract valued at up to $545 million to ATCC to aid NIAID's research efforts in infectious and allergic diseases.

Under the indefinite delivery/indefinite quality contract, ATCC will support NIAID's Division of Clinical Research, Division of Intramural Research, and the Vaccine Research Center by providing rapid response capabilities to infectious diseases, such as COVID-19, as well as services, like assay development and vaccine production.

ATCC is a biological materials and information resource and standards organization, as well as a developer and supplier of authenticated cell lines and microorganisms.

L7 inks deal with ATCC
L7 Informatics has signed an agreement with the American Type Culture Collection (ATCC) to enhance the digitalization of its manufacturing and laboratory...
NIH grants Vaxess $2.9M to develop vaccine patch
Vaxess Technologies announced it has received a $2.9 million grant from the National Institute of Allergy and Infectious Diseases, an agency of the...
National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter